METHOD FOR DIAGNOSTICS AND TREATMENT OF OBLIGATE PRECANCER DISEASES AND CA IN SITU Russian patent published in 2023 - IPC A61B5/01 A61N5/02 G01N33/574 C12Q1/6851 C12Q1/6886 A61B6/00 A61B8/08 

FIELD: medicine; oncology.

SUBSTANCE: patient undergoes mammography — MMG, ultrasound — ultrasound, radiothermometry — RTM. At the same time, the microRNA oncopanel is isolated from saliva, including miR-199a-3p, miR-214-3p, miR-25, miR-26a, miR-99a, miR-184, miR-222-3p, let-7a-5p, miR-24-3p, miR-195, miR-21-5p, miR-155. When detecting such changes in the microRNA oncopanel as a decrease in the concentration of hsa-let-7a-5p, an increase in the concentration of hsa-miR-214-3p, a decrease in the concentration of hsa-miR-21-5p, a decrease in the concentration of hsa-miR-184, an increase in the concentration hsa-miR-195, an increase in the concentration of hsa-miR-155 and the detection of pathological foci in the mammary glands in the form of cysts, fibroadenomas, localized adenosis, intraductal papillomas and Ca in situ of the mammary glands, perform a local injection of a photosensitizer 0.35% solution into the pathological focus radachlorin 0.01–0.1 ml and intravenous administration of 0.35% radachlorin solution and 1 ml of refnot. Perform laser photoimmunotherapy with a wavelength of 662 nm, also prescribe taurine (dibicor) 0.5 g 2 times a day for 1 month.

EFFECT: method provides an opportunity to isolate a group of obligate precancers and Ca in situ from a mass of diseases, as well as to successfully treat these diseases.

1 cl, 1 tbl, 2 ex